BACKGROUND: Both balanced crystalloids and saline are used for intravenous fluid administration in critically ill adults, but it is not known which results in better clinical outcomes. METHODS: In a pragmatic, cluster-randomized, multiple-crossover trial conducted in five intensive care units at an academic center, we assigned 15,802 adults to receivesaline (0.9% sodium chloride) or balanced crystalloids (lactated Ringer's solution or Plasma-Lyte A) according to the randomization of the unit to which they were admitted. The primary outcome was a major adverse kidney event within 30 days - a composite of death from any cause, new renal-replacement therapy, or persistent renal dysfunction (defined as an elevation of the creatinine level to ≥200% of baseline) - all censored at hospital discharge or 30 days, whichever occurred first. RESULTS: Among the 7942 patients in thebalanced-crystalloids group, 1139 (14.3%) had a major adverse kidney event, as compared with 1211 of 7860 patients (15.4%) in the saline group (marginal odds ratio, 0.91; 95% confidence interval [CI], 0.84 to 0.99; conditional odds ratio, 0.90; 95% CI, 0.82 to 0.99; P=0.04). In-hospital mortality at 30 days was 10.3% in the balanced-crystalloids group and 11.1% in the saline group (P=0.06). The incidence of new renal-replacement therapy was 2.5% and 2.9%, respectively (P=0.08), and the incidence of persistent renal dysfunction was 6.4% and 6.6%, respectively (P=0.60). CONCLUSIONS: Among critically ill adults, the use of balanced crystalloids for intravenous fluid administration resulted in a lower rate of the composite outcome of death from any cause, new renal-replacement therapy, or persistent renal dysfunction than the use of saline. (Funded by the Vanderbilt Institute for Clinical and Translational Research and others; SMART-MED and SMART-SURG ClinicalTrials.gov numbers, NCT02444988 and NCT02547779 .).
RCT Entities:
BACKGROUND: Both balanced crystalloids and saline are used for intravenous fluid administration in critically ill adults, but it is not known which results in better clinical outcomes. METHODS: In a pragmatic, cluster-randomized, multiple-crossover trial conducted in five intensive care units at an academic center, we assigned 15,802 adults to receive saline (0.9% sodium chloride) or balanced crystalloids (lactated Ringer's solution or Plasma-Lyte A) according to the randomization of the unit to which they were admitted. The primary outcome was a major adverse kidney event within 30 days - a composite of death from any cause, new renal-replacement therapy, or persistent renal dysfunction (defined as an elevation of the creatinine level to ≥200% of baseline) - all censored at hospital discharge or 30 days, whichever occurred first. RESULTS: Among the 7942 patients in the balanced-crystalloids group, 1139 (14.3%) had a major adverse kidney event, as compared with 1211 of 7860 patients (15.4%) in the saline group (marginal odds ratio, 0.91; 95% confidence interval [CI], 0.84 to 0.99; conditional odds ratio, 0.90; 95% CI, 0.82 to 0.99; P=0.04). In-hospital mortality at 30 days was 10.3% in the balanced-crystalloids group and 11.1% in the saline group (P=0.06). The incidence of new renal-replacement therapy was 2.5% and 2.9%, respectively (P=0.08), and the incidence of persistent renal dysfunction was 6.4% and 6.6%, respectively (P=0.60). CONCLUSIONS: Among critically ill adults, the use of balanced crystalloids for intravenous fluid administration resulted in a lower rate of the composite outcome of death from any cause, new renal-replacement therapy, or persistent renal dysfunction than the use of saline. (Funded by the Vanderbilt Institute for Clinical and Translational Research and others; SMART-MED and SMART-SURG ClinicalTrials.gov numbers, NCT02444988 and NCT02547779 .).
Authors: Bram Rochwerg; Waleed Alhazzani; Anees Sindi; Diane Heels-Ansdell; Lehana Thabane; Alison Fox-Robichaud; Lawrence Mbuagbaw; Wojciech Szczeklik; Fayez Alshamsi; Sultan Altayyar; Wang-Chun Ip; Guowei Li; Michael Wang; Anna Wludarczyk; Qi Zhou; Gordon H Guyatt; Deborah J Cook; Roman Jaeschke; Djillali Annane Journal: Ann Intern Med Date: 2014-09-02 Impact factor: 25.391
Authors: Feihu Zhou; Zhi-Yong Peng; Jeffery V Bishop; Matthew E Cove; Kai Singbartl; John A Kellum Journal: Crit Care Med Date: 2014-04 Impact factor: 7.598
Authors: Nor'azim Mohd Yunos; Rinaldo Bellomo; Colin Hegarty; David Story; Lisa Ho; Michael Bailey Journal: JAMA Date: 2012-10-17 Impact factor: 56.272
Authors: Wesley H Self; Matthew W Semler; Jonathan P Wanderer; Li Wang; Daniel W Byrne; Sean P Collins; Corey M Slovis; Christopher J Lindsell; Jesse M Ehrenfeld; Edward D Siew; Andrew D Shaw; Gordon R Bernard; Todd W Rice Journal: N Engl J Med Date: 2018-02-27 Impact factor: 91.245
Authors: Simon Finfer; Bette Liu; Colman Taylor; Rinaldo Bellomo; Laurent Billot; Deborah Cook; Bin Du; Colin McArthur; John Myburgh Journal: Crit Care Date: 2010-10-15 Impact factor: 9.097
Authors: Naomi E Hammond; Colman Taylor; Simon Finfer; Flavia R Machado; YouZhong An; Laurent Billot; Frank Bloos; Fernando Bozza; Alexandre Biasi Cavalcanti; Maryam Correa; Bin Du; Peter B Hjortrup; Yang Li; Lauralyn McIntryre; Manoj Saxena; Frédérique Schortgen; Nicola R Watts; John Myburgh Journal: PLoS One Date: 2017-05-12 Impact factor: 3.240
Authors: Kianoush Kashani; Ali Al-Khafaji; Thomas Ardiles; Antonio Artigas; Sean M Bagshaw; Max Bell; Azra Bihorac; Robert Birkhahn; Cynthia M Cely; Lakhmir S Chawla; Danielle L Davison; Thorsten Feldkamp; Lui G Forni; Michelle Ng Gong; Kyle J Gunnerson; Michael Haase; James Hackett; Patrick M Honore; Eric A J Hoste; Olivier Joannes-Boyau; Michael Joannidis; Patrick Kim; Jay L Koyner; Daniel T Laskowitz; Matthew E Lissauer; Gernot Marx; Peter A McCullough; Scott Mullaney; Marlies Ostermann; Thomas Rimmelé; Nathan I Shapiro; Andrew D Shaw; Jing Shi; Amy M Sprague; Jean-Louis Vincent; Christophe Vinsonneau; Ludwig Wagner; Michael G Walker; R Gentry Wilkerson; Kai Zacharowski; John A Kellum Journal: Crit Care Date: 2013-02-06 Impact factor: 9.097
Authors: Erin K Stenson; Natalie Z Cvijanovich; Geoffrey L Allen; Neal J Thomas; Michael T Bigham; Scott L Weiss; Julie C Fitzgerald; Parag N Jain; Keith Meyer; Michael Quasney; Mark Hall; Rainer Gedeit; Robert J Freishtat; Jeffrey Nowak; Riad Lutfi; Shira Gertz; Jocelyn R Grunwell; Hector R Wong; Nick Anas Journal: Intensive Care Med Date: 2018-10-15 Impact factor: 17.440
Authors: Andrew Friederich; Natalie Martin; Morgan B Swanson; Brett A Faine; Nicholas M Mohr Journal: Ann Emerg Med Date: 2018-08-23 Impact factor: 5.721
Authors: David A C Messerer; Rebecca Halbgebauer; Bo Nilsson; Hermann Pavenstädt; Peter Radermacher; Markus Huber-Lang Journal: Nat Rev Nephrol Date: 2020-09-21 Impact factor: 28.314